🇺🇸 FDA
Pipeline program

E7777 9 mcg/kg

E7777-G000-302

Phase 3 small_molecule completed

Quick answer

E7777 9 mcg/kg for Persistent or Recurrent Cutaneous T-Cell Lymphoma is a Phase 3 program (small_molecule) at CITIUS ONCOLOGY, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CITIUS ONCOLOGY, INC.
Indication
Persistent or Recurrent Cutaneous T-Cell Lymphoma
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials